KNOWLEDGE PORTAL
on innovation and access to medicines

This organization was included for its participation in non profit R&D for Neglected Diseases (Vieira M, Kimmitt R and Moon S.  F1000Research 2021, 10:190)

This organization was included for its participation in non profit R&D for Neglected Diseases (Vieira M, Kimmitt R and Moon S.  F1000Research 2021, 10:190)

This organization was included for its participation in non profit R&D for Neglected Diseases (Vieira M, Kimmitt R and Moon S.  F1000Research 2021, 10:190)

UCAB (a collaboration between Utrecht University and the World Health Organization) is a “non-profit foundation that contributes to the shared goals of both organizations in promoting the wide availability of high quality, safe and affordable biotherapeutics in low- and middle-income countries (LMICs)...UCAB focuses on the development of biotherapeutics with the greatest impact on public health in LMICs, which are preferably included in the Essential Medicines List (EML) or the Neglected Tropical Disease (NTD) portfolio of the World Health Organization” (Utrecht University, n.d.).

“Venatorx Pharmaceuticals is a private company that is focused on the discovery and development of novel anti-infectives to treat multi-drug-resistant (MDR) bacterial infections and hard-to-treat viral infections…Venatorx’s two lead antibacterial clinical-stage programs are intravenous (cefepime-taniborbactam) and oral (ceftibuten/VNRX-7145) broad-spectrum beta-lactam / beta-lactamase inhibitor combinations that are in Phase 3 and Phase 1, respectively. In addition, the first Venatorx antiviral compound (VNRX-9945), a Hepatitis B virus inhibitor, has advanced to Phase 1 clinical development” (Venatorx, n.d.).

“Wellcome Leap builds bold, unconventional programs, and funds them at scale. Programs that aim to deliver breakthroughs in human health over 5 – 10 years and demonstrate seemingly impossible results on seemingly impossible timelines. Wellcome Leap is a global ARPA for health” (Wellcome Leap, n.d.). Wellcome Leap’s R3 program has two goals: “one, to increase exponentially the number of biologic products that can be designed, developed, and produced every year, reducing their costs and increasing equitable access; and two, to create a self-sustaining network of manufacturing facilities providing globally distributed, state-of-the-art surge capacity to meet future pandemic needs” (ibid).

“Patents for Humanity is the United States Patent and Trademark Office's (USPTO) awards competition recognizing innovators who use game-changing technology to meet global humanitarian challenges. The program provides business incentives for reaching those in need: winners receive an acceleration certificate to expedite select proceedings at the USPTO, as well as public recognition of their work. The awards showcase how patent holders with vision are pioneering innovative ways to provide affordable, scalable, and sustainable solutions for the less fortunate” (USPTO, n.d.).

This initiative was selected based on its inclusion in the report “RE:ROUTE, A map of the alternative biomedical R&D landscape”, (Kiddell-Monroe, Greenberg, and Basey 2016)

This organization was included for its participation in non profit R&D for Neglected Diseases (Vieira M, Kimmitt R and Moon S.  F1000Research 2021, 10:190)

This organization was included for its participation in non profit R&D for Neglected Diseases (Vieira M, Kimmitt R and Moon S.  F1000Research 2021, 10:190)

VacEquity Global Health (VGH) was “founded in May 2020 to support fast-track development and global distribution of Imperial's COVID-19 vaccine candidate” (Imperial College London, 2021). VacEquity Global Health has since closed, but “Imperial [College London] and its partners, including VaxEquity (VXT), will continue to seek to develop self-amplifying RNA vaccines that can ultimately be distributed to the widest possible global population at low cost, including for low- and middle-income countries” (ibid).

This organization was included for its participation in non profit R&D for Neglected Diseases (Vieira M, Kimmitt R and Moon S.  F1000Research 2021, 10:190)

“Wellcome is a global charitable foundation established in 1936. Through our work we support science to solve the urgent health issues facing everyone. We fund curiosity-driven research, and we’re taking on three of the biggest health challenges facing humanity – climate change, infectious disease and mental health. With a £37.8 billion investment portfolio, we give researchers the time and resources they need to make breakthroughs. We also work with policy makers, run advocacy campaigns, and form partnerships with other organisations to ensure everyone, everywhere benefits from advances in health science” (Wellcome Trust, n.d.).